Immutep Limited (PRRUF)
USD 0.2
(-26.74%)
USD 0.2
(-26.74%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 | 201.57 Million AUD | 36.71% |
| 2023 | 147.44 Million AUD | 44.32% |
| 2022 | 102.16 Million AUD | 24.55% |
| 2021 | 82.03 Million AUD | 76.04% |
| 2020 | 46.59 Million AUD | 14.94% |
| 2019 | 40.54 Million AUD | -13.74% |
| 2018 | 46.99 Million AUD | 34.42% |
| 2017 | 34.96 Million AUD | -17.84% |
| 2016 | 42.55 Million AUD | 37.34% |
| 2015 | 30.98 Million AUD | 22.09% |
| 2014 | 25.37 Million AUD | -22.66% |
| 2013 | 32.81 Million AUD | -21.14% |
| 2012 | 41.61 Million AUD | -27.81% |
| 2011 | 57.64 Million AUD | 203.19% |
| 2010 | 19.01 Million AUD | 663.62% |
| 2009 | 2.48 Million AUD | -11.75% |
| 2008 | 2.82 Million AUD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 FY | 201.57 Million AUD | 36.71% |
| 2024 Q2 | 123.78 Million AUD | 0.0% |
| 2024 Q4 | 201.57 Million AUD | 0.0% |
| 2023 Q2 | 86 Million AUD | 0.0% |
| 2023 Q4 | 147.44 Million AUD | 0.0% |
| 2023 FY | 147.44 Million AUD | 44.32% |
| 2022 FY | 102.16 Million AUD | 24.55% |
| 2022 Q4 | 102.16 Million AUD | 0.0% |
| 2022 Q2 | 120.2 Million AUD | 0.0% |
| 2021 Q2 | 76.47 Million AUD | 0.0% |
| 2021 FY | 82.03 Million AUD | 76.04% |
| 2021 Q4 | 82.03 Million AUD | 0.0% |
| 2020 Q4 | 46.59 Million AUD | 0.0% |
| 2020 FY | 46.59 Million AUD | 14.94% |
| 2020 Q2 | 42.95 Million AUD | 0.0% |
| 2019 FY | 40.54 Million AUD | -13.74% |
| 2019 Q4 | 40.54 Million AUD | 0.0% |
| 2019 Q2 | 48.23 Million AUD | 0.0% |
| 2018 Q4 | 46.99 Million AUD | 0.0% |
| 2018 Q2 | 37.04 Million AUD | 0.0% |
| 2018 FY | 46.99 Million AUD | 34.42% |
| 2017 Q4 | 34.96 Million AUD | -1.11% |
| 2017 Q3 | 35.35 Million AUD | -7.35% |
| 2017 Q2 | 38.15 Million AUD | 0.0% |
| 2017 FY | 34.96 Million AUD | -17.84% |
| 2016 Q2 | 48.24 Million AUD | 0.0% |
| 2016 FY | 42.55 Million AUD | 37.34% |
| 2016 Q4 | 42.55 Million AUD | 0.0% |
| 2015 FY | 30.98 Million AUD | 22.09% |
| 2015 Q4 | 30.98 Million AUD | 0.0% |
| 2015 Q2 | 39.31 Million AUD | 0.0% |
| 2014 FY | 25.37 Million AUD | -22.66% |
| 2014 Q4 | 25.37 Million AUD | 0.0% |
| 2014 Q2 | 32.81 Million AUD | 0.0% |
| 2013 Q4 | 32.81 Million AUD | 0.0% |
| 2013 FY | 32.81 Million AUD | -21.14% |
| 2013 Q2 | 32.34 Million AUD | 0.0% |
| 2012 FY | 41.61 Million AUD | -27.81% |
| 2012 Q4 | 41.61 Million AUD | 0.0% |
| 2011 FY | 57.64 Million AUD | 203.19% |
| 2010 FY | 19.01 Million AUD | 663.62% |
| 2009 FY | 2.48 Million AUD | -11.75% |
| 2008 FY | 2.82 Million AUD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Nuo Therapeutics, Inc. | 1.87 Million USD | -10634.407% |
| CNBX Pharmaceuticals Inc. | 499.03 Thousand USD | -40293.492% |
| Mosaic ImmunoEngineering Inc. | 261.27 Thousand USD | -77051.56% |
| Evofem Biosciences, Inc. | 10.55 Million USD | -1809.98% |
| GB Sciences, Inc. | 103.44 Thousand USD | -194771.794% |
| Inhibitor Therapeutics, Inc. | 8.94 Million USD | -2152.495% |
| NanoSphere Health Sciences Inc. | 17.88 Thousand USD | -1127300.9% |
| Skye Bioscience, Inc. | 11.94 Million USD | -1588.211% |
| Zenith Capital Corp. | 7410.00 USD | -2720268.165% |
| Agentix Corp. | 261.39 Thousand USD | -77017.617% |
| Arch Therapeutics, Inc. | 1.95 Million USD | -10194.169% |
| Biomind Labs Inc. | 73.81 Thousand USD | -272972.354% |
| ContraFect Corporation | 20.67 Million USD | -874.802% |
| CSL Limited | 38.02 Billion USD | 99.47% |
| CytoDyn Inc. | 11.13 Million USD | -1710.159% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| Neon Bloom, Inc. | 770.64 Thousand USD | -26057.25% |
| Northwest Biotherapeutics, Inc. | 27.94 Million USD | -621.369% |
| ProtoKinetix, Incorporated | 480.55 Thousand USD | -41847.008% |
| Propanc Biopharma, Inc. | 72.36 Thousand USD | -278459.084% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -56904.975% |
| Santhera Pharmaceuticals Holding AG | 130.21 Million USD | -54.81% |
| SQZ Biotechnologies Company | 107.18 Million USD | -88.063% |
| Therapeutic Solutions International, Inc. | 3.31 Million USD | -5984.472% |
| Eiger BioPharmaceuticals, Inc. | 38.84 Million USD | -418.906% |
| Intellipharmaceutics International Inc. | 1.43 Million USD | -13976.451% |
| Mesoblast Limited | 667.9 Million USD | 69.819% |
| Marizyme, Inc. | 22.01 Million USD | -815.642% |
| Genus plc | 1.02 Billion USD | 80.408% |
| Pharming Group N.V. | 462.85 Million USD | 56.449% |
| Nymox Pharmaceutical Corporation | 627 Thousand USD | -32049.806% |
| RegeneRx Biopharmaceuticals, Inc. | 382.17 Thousand USD | -52645.006% |
| IMV Inc. | 31.33 Million USD | -543.329% |
| AXIM Biotechnologies, Inc. | 4.14 Million USD | -4761.993% |
| MultiCell Technologies, Inc. | 126.22 USD | -159704606.861% |
| ONE Bio Corp. | 70.08 Million USD | -187.619% |
| RVL Pharmaceuticals plc | 128.51 Million USD | -56.859% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| Emmaus Life Sciences, Inc. | 35.17 Million USD | -473.01% |
| Provectus Biopharmaceuticals, Inc. | 1.44 Million USD | -13813.121% |
| Oncotelic Therapeutics, Inc. | 30.01 Million USD | -571.596% |
| THC Farmaceuticals, Inc. | 2.74 Million USD | -7239.938% |
| Acro Biomedical Co., Ltd. | 687.48 Thousand USD | -29221.22% |
| Alpha Cognition Inc. | 2.45 Million USD | -8120.445% |
| Enzolytics Inc. | 361.7 Million USD | 44.27% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 4.54 Billion USD | 95.562% |
| Enzon Pharmaceuticals, Inc. | 47.7 Million USD | -322.58% |
| Endonovo Therapeutics, Inc. | 639.65 Thousand USD | -31413.701% |
| Genscript Biotech Corporation | 3.38 Billion USD | 94.047% |
| Nanobac Pharmaceuticals, Incorporated | 7.21 Million USD | -2692.049% |
| Institute of Biomedical Research Corp. | 76.35 Thousand USD | -263906.183% |
| Sigyn Therapeutics, Inc. | 321.8 Thousand USD | -62540.001% |
| WPD Pharmaceuticals Inc. | 261.36 Thousand USD | -77025.878% |
| Cotinga Pharmaceuticals Inc. | 927.96 Thousand USD | -21622.818% |
| VioQuest Pharmaceuticals, Inc. | 1.35 Million USD | -14739.978% |
| PsyBio Therapeutics Corp. | 390.36 Thousand USD | -51538.534% |
| Adynxx, Inc. | - USD | -Infinity% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| Accustem Sciences Inc. | 939.68 Thousand USD | -21351.702% |
| Helix BioMedix, Inc. | 3.02 Million USD | -6563.588% |
| EV Biologics, Inc. | 431.71 Thousand USD | -46592.783% |
| Q BioMed Inc. | 3.51 Million USD | -5633.987% |
| Capstone Therapeutics Corp. | 52.7 Million USD | -282.496% |
| American Oriental Bioengineering, Inc. | 446.3 Million USD | 54.834% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| BioStem Technologies, Inc. | 14.56 Million USD | -1284.445% |
| Curative Biotechnology, Inc. | 2.6 Million USD | -7643.531% |
| HST Global, Inc. | 1526.00 USD | -13209551.442% |
| Burzynski Research Institute, Inc. | 2310.00 USD | -8726275.801% |
| Wesana Health Holdings Inc. | 987.96 Thousand USD | -20303.443% |
| Halberd Corporation | 10.13 Thousand USD | -1989627.381% |
| Resverlogix Corp. | 8.11 Million USD | -2384.033% |
| Cell Source, Inc. | 195.17 Thousand USD | -103183.419% |
| RespireRx Pharmaceuticals Inc. | 22.78 Thousand USD | -884757.034% |
| GeneThera, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | 7.37 Million USD | -2632.479% |
| Ember Therapeutics, Inc. | 184.00 USD | -109553857.065% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| NovAccess Global Inc. | 62.24 Thousand USD | -323732.542% |
| Kadimastem Ltd | 2.3 Million USD | -8648.797% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Rasna Therapeutics, Inc. | 95.65 Thousand USD | -210631.343% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 57.09 Thousand USD | -352965.613% |
| LadRx Corporation | 2.3 Million USD | -8634.384% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -56904.975% |
| Affymax, Inc. | 7.44 Million USD | -2608.307% |
| Itoco Inc. | 1.4 Million USD | -14297.78% |
| Pathfinder Cell Therapy, Inc. | 106 Thousand USD | -190069.133% |
| Mobile Lads Corp. | 52.00 USD | -387652363.462% |
| International Stem Cell Corporation | 5.39 Million USD | -3639.875% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| Bioxytran, Inc. | 137.63 Thousand USD | -146356.125% |
| NDT Pharmaceuticals Inc. | 142.97 Thousand USD | -140892.139% |
| Qrons Inc. | 420.00 USD | -47994966.905% |
| Alseres Pharmaceuticals, Inc. | 385.47 Thousand USD | -52194.279% |
| SYBLEU INC | 330.46 Thousand USD | -60898.124% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 552.12 Thousand USD | -36410.049% |
| Rebus Holdings, Inc. | 5000.00 USD | -4031485.62% |
| ImmunoCellular Therapeutics, Ltd. | 409.42 Thousand USD | -49135.088% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 15 Million USD | -1243.698% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 16.57 Million USD | -1115.871% |
| Adhera Therapeutics, Inc. | 79 Thousand USD | -255063.647% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 864.67 Thousand USD | -23212.668% |
| Innovation Pharmaceuticals Inc. | 7.51 Million USD | -2581.645% |
| Neutra Corp. | 2851.00 USD | -7070376.359% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | -522.043% |
| PureTech Health plc | 693.97 Million USD | 70.953% |
| Coeptis Therapeutics, Inc. | 8.07 Million USD | -2397.547% |
| IXICO plc | 15.84 Million USD | -1172.283% |
| IntelGenx Technologies Corp. | 8.28 Million USD | -2333.944% |
| Gelesis Holdings, Inc. | 103.32 Million USD | -95.094% |
| CSL Limited | 38.02 Billion USD | 99.47% |
| Cellectis S.A. | 333.99 Million USD | 39.646% |